Gyre Therapeutics (GYRE) Cash & Current Investments (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Cash & Current Investments data on file, last reported at $49.8 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $49.8 million, up 169.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.8 million (up 169.43% YoY), and the FY2025 annual result was $40.3 million, up 50.85% from the prior year.
• Cash & Current Investments improved to $49.8 million in Q1 2026 per GYRE's latest filing, from $40.3 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $75.4 million in Q2 2022 and troughed at $2.2 million in Q3 2023.
• A 5-year average of $31.0 million and a median of $25.2 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments plunged 90.48% in 2023, then surged 1039.36% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $25.2 million in 2022, then soared by 33.1% to $33.5 million in 2023, then retreated by 20.32% to $26.7 million in 2024, then soared by 50.85% to $40.3 million in 2025, then rose by 23.66% to $49.8 million in 2026.
• Business Quant data shows GYRE's Cash & Current Investments at $49.8 million in Q1 2026, $40.3 million in Q4 2025, and $60.0 million in Q3 2025.